The DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
New Drugs against Tuberculosis: Problems, Progress, and Evaluation of Agents in Clinical Development
Open accessAbstract
Contains fulltext : 81187.pdf (Publisher’s version ) (Open Access)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence
Cole, S. T., Brosch, R., Parkhill, J., Garnier, T., Churcher, C., Harris, D., Gordon, S. V., Eiglmeier, K., Gas, S., Barry, C. E., et al. (1998) · Nature · doi:10.1038/31159 · Cited by 7,847
A Diarylquinoline Drug Active on the ATP Synthase of Mycobacterium tuberculosis
Andries, K., Verhasselt, P., Guillemont, J., Göhlmann, H. W. H., Neefs, J.-M., Winkler, H., Van Gestel, J., Timmerman, P., Zhu, M., Lee, E., et al. (2005) · Science · doi:10.1126/science.1106753 · Cited by 2,191 · cited 7×
“120 g/ml in both fully susceptible and MDR strains (4, 59).”
BackgroundInfluential(2003) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.167.4.603 · Cited by 1,944
WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update
Falzon, D., Jaramillo, E., Schünemann, H. J., Arentz, M., Bauer, M., Bayona, J., Blanc, L., Caminero, J. A., Daley, C. L., Duncombe, C., et al. (2011) · European Respiratory Journal · doi:10.1183/09031936.00073611 · Cited by 1,100
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Pharmacokinetic Interactions with Rifampicin: Clinical Relevance
Niemi, M., Backman, J. T., Fromm, M. F., Neuvonen, P. J., & Kivist??, K. T. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342090-00003 · Cited by 764
Matsumoto, M., Hashizume, H., Tomishige, T., Kawasaki, M., Tsubouchi, H., Sasaki, H., Shimokawa, Y., & Komatsu, M. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030466 · Cited by 751
DNA Gyrase and the Supercoiling of DNA
Cozzarelli, N. R. (1980) · Science · doi:10.1126/science.6243420 · Cited by 711
Treatment of Multidrug-Resistant Tuberculosis
Wood, A. J. J., & Iseman, M. D. (1993) · New England Journal of Medicine · doi:10.1056/nejm199309093291108 · Cited by 706
Anti-tuberculosis drug resistance in the world
Wilkinson, D. (1998) · Transactions of the Royal Society of Tropical Medicine and Hygiene · doi:10.1016/s0035-9203(98)90766-0 · Cited by 700
Directly observed therapy for treating tuberculosis
Karumbi, J., & Garner, P. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003343.pub4 · Cited by 644
Paradoxical Worsening of Tuberculosis Following Antiretroviral Therapy in Patients with AIDS
NARITA, M., ASHKIN, D., HOLLENDER, E. S., & PITCHENIK, A. E. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.158.1.9712001 · Cited by 608
Pharmacodynamics of Levofloxacin: A New Paradigm for Early Clinical Trials
Preston, S. L. (1998) · JAMA · doi:10.1001/jama.279.2.125 · Cited by 589
Drusano, G. L., Johnson, D. E., Rosen, M., & Standiford, H. C. (1993) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.37.3.483 · Cited by 426
Evolution of Drug Resistance in Mycobacterium tuberculosis : Clinical and Molecular Perspective
Gillespie, S. H. (2002) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.46.2.267-274.2002 · Cited by 412
Clinical Pharmacokinetics of Rifampicin
Acocella, G. (1978) · Clinical Pharmacokinetics · doi:10.2165/00003088-197803020-00002 · Cited by 405
Fluoroquinolones, tuberculosis, and resistance
Ginsburg, A. S., Grosset, J. H., & Bishai, W. R. (2003) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(03)00671-6 · Cited by 403
Outpatient gatifloxacin therapy and dysglycemia in older adults.
Park-Wyllie, L. Y., Juurlink, D. N., Kopp, A., Shah, B. R., Stukel, T. A., Stumpo, C., Dresser, L., Low, D. E., & Mamdani, M. M. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055191 · Cited by 367
Global Tuberculosis Programme, & Disease, L. (1997) · Medical Entomology and Zoology · Cited by 361
Application of fluoroquinolone pharmacodynamics
Wright, D. H. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.5.669 · Cited by 342
Comparative Pharmacokinetics and Pharmacodynamics of the Rifamycin Antibacterials
Burman, W. J., Gallicano, K., & Peloquin, C. (2001) · Clinical Pharmacokinetics · doi:10.2165/00003088-200140050-00002 · Cited by 337
Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of Tuberculosis
Jayaram, R., Gaonkar, S., Kaur, P., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharat, S., Shandil, R. K., Kantharaj, E., et al. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.7.2118-2124.2003 · Cited by 335
Manjunatha, U. H., Boshoff, H., Dowd, C. S., Zhang, L., Albert, T. J., Norton, J. E., Daniels, L., Dick, T., Pang, S. S., & Barry, C. E. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0508392103 · Cited by 331
Rustomjee, R., Lienhardt, C., Kanyok, T. P., Davies, G., Levin, J., Mthiyane, T., Reddy, C., Sturm, A. W., Sirgel, F. A., Allen, J., et al. (2008) · PubMed · Cited by 326
Role of individual drugs in the chemotherapy of tuberculosis.
Mitchison, D. A. (2000) · PubMed · Cited by 319
Moxifloxacin-containing Regimen Greatly Reduces Time to Culture Conversion in Murine Tuberculosis
Nuermberger, E. L., Yoshimatsu, T., Tyagi, S., O'Brien, R. J., Vernon, A. N., Chaisson, R. E., Bishai, W. R., & Grosset, J. H. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200310-1380oc · Cited by 314
Vernon, A., Burman, W., Benator, D., Khan, A., & Bozeman, L. (1999) · The Lancet · doi:10.1016/s0140-6736(98)11467-8 · Cited by 308
Lenaerts, A. J., Gruppo, V., Marietta, K. S., Johnson, C. M., Driscoll, D. K., Tompkins, N. M., Rose, J. D., Reynolds, R. C., & Orme, I. M. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.6.2294-2301.2005 · Cited by 306
Peters, D. H., & Clissold, S. P. (1992) · Drugs · doi:10.2165/00003495-199244010-00009 · Cited by 295
Moxifloxacin versus Ethambutol in the First 2 Months of Treatment for Pulmonary Tuberculosis
Burman, W. J., Goldberg, S., Johnson, J. L., Muzanye, G., Engle, M., Mosher, A. W., Choudhri, S., Daley, C. L., Munsiff, S. S., Zhao, Z., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200603-360oc · Cited by 286
Challenges in tuberculosis drug research and development
Ginsberg, A. M., & Spigelman, M. (2007) · Nature Medicine · doi:10.1038/nm0307-290 · Cited by 283
Rustomjee, R., Diacon, A. H., Allen, J., Venter, A., Reddy, C., Patientia, R. F., Mthiyane, T. C. P., De Marez, T., van Heeswijk, R., Kerstens, R., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01204-07 · Cited by 278
Location of Persisting Mycobacteria in a Guinea Pig Model of Tuberculosis Revealed by R207910
Lenaerts, A. J., Hoff, D., Aly, S., Ehlers, S., Andries, K., Cantarero, L., Orme, I. M., & Basaraba, R. J. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00276-07 · Cited by 257
Heep, M., Brandstätter, B., Rieger, U., Lehn, N., Richter, E., Rüsch-Gerdes, S., & Niemann, S. (2001) · Journal of Clinical Microbiology · doi:10.1128/jcm.39.1.107-110.2001 · Cited by 240
Williams, D. L., Spring, L., Collins, L., Miller, L. P., Heifets, L. B., Gangadharam, P. R. J., & Gillis, T. P. (1998) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.42.7.1853 · Cited by 236
Pharmacodynamics and pharmacokinetics of SQ109, a new diamine‐based antitubercular drug
Jia, L., Tomaszewski, J. E., Hanrahan, C., Coward, L., Noker, P., Gorman, G., Nikonenko, B., & Protopopova, M. (2005) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705984 · Cited by 231
The Need for New Drugs against Tuberculosis
O'BRIEN, R. J., & NUNN, P. P. (2001) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.163.5.2007122 · Cited by 221
Tuberculosis therapy: past, present and future
Iseman, M. D. (2002) · European Respiratory Journal · doi:10.1183/09031936.02.00309102 · Cited by 207
Daily Dosing of Rifapentine Cures Tuberculosis in Three Months or Less in the Murine Model
Rosenthal, I. M., Zhang, M., Williams, K. N., Peloquin, C. A., Tyagi, S., Vernon, A. A., Bishai, W. R., Chaisson, R. E., Grosset, J. H., & Nuermberger, E. L. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040344 · Cited by 205
Shandil, R. K., Jayaram, R., Kaur, P., Gaonkar, S., Suresh, B. L., Mahesh, B. N., Jayashree, R., Nandi, V., Bharath, S., & Balasubramanian, V. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00414-06 · Cited by 203
Jasmer, R. M., Saukkonen, J. J., Blumberg, H. M., Daley, C. L., Bernardo, J., Vittinghoff, E., King, M. D., Kawamura, L. M., Hopewell, P. C., & for the Short-Course Rifampin and Pyrazinamide for Tuberculosis Infection (SCRIPT) Study Investigators* (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-8-200210150-00007 · Cited by 201
Persistent and dormant tubercle bacilli and latent tuberculosis
Zhang, Y. (2004) · Frontiers in Bioscience · doi:10.2741/1291 · Cited by 195
Diacon, A. H., Patientia, R. F., Venter, A., van Helden, P. D., Smith, P. J., McIlleron, H., Maritz, J. S., & Donald, P. R. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01474-06 · Cited by 193
Hu, Y., Coates, A. R. M., & Mitchison, D. A. (2003) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.47.2.653-657.2003 · Cited by 187
Lubasch, A., Keller, I., Borner, K., et al. (2000) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.44.10.2600-2603.2000 · Cited by 186
Peloquin, C. A., Hadad, D. J., Molino, L. P. D., Palaci, M., Boom, W. H., Dietze, R., & Johnson, J. L. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01036-07 · Cited by 185
Directly observed therapy for treating tuberculosis
Volmink, J. A., & Garner, P. (2007) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003343.pub3 · Cited by 177
Synergistic Activity of R207910 Combined with Pyrazinamide against Murine Tuberculosis
Ibrahim, M., Andries, K., Lounis, N., Chauffour, A., Truffot-Pernot, C., Jarlier, V., & Veziris, N. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00898-06 · Cited by 175
In Vitro Antimycobacterial Spectrum of a Diarylquinoline ATP Synthase Inhibitor
Huitric, E., Verhasselt, P., Andries, K., & Hoffner, S. E. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00181-07 · Cited by 172
New Tuberculosis Therapeutics: A Growing Pipeline
Spigelman, M. K. (2007) · The Journal of Infectious Diseases · doi:10.1086/518663 · Cited by 169
Rifampicin Reduces Plasma Concentrations of Moxifloxacin in Patients with Tuberculosis
Nijland, H. M. J., Ruslami, R., Suroto, A. J., Burger, D. M., Alisjahbana, B., van Crevel, R., & Aarnoutse, R. E. (2007) · Clinical Infectious Diseases · doi:10.1086/521894 · Cited by 166
Self-citationChen, P. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl227 · Cited by 164
Genetic Basis for Natural and Acquired Resistance to the Diarylquinoline R207910 in Mycobacteria
Petrella, S., Cambau, E., Chauffour, A., Andries, K., Jarlier, V., & Sougakoff, W. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00244-06 · Cited by 147
Moxifloxacin (BAY12-8039), a New 8-Methoxyquinolone, Is Active in a Mouse Model of Tuberculosis
Miyazaki, E., Miyazaki, M., Chen, J. M., et al. (1999) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.43.1.85 · Cited by 145
Schechter, M., Zajdenverg, R., Falco, G., Barnes, G. L., Faulhaber, J. C., Coberly, J. S., Moore, R. D., & Chaisson, R. E. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200512-1953oc · Cited by 144
Nikonenko, B. V., Protopopova, M. N., Samala, R., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01326-06 · Cited by 143
Use of genomics and combinatorial chemistry in the development of new antimycobacterial drugs
Barry, C. E., Slayden, R. A., Sampson, A. E., & Lee, R. E., Jr. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00253-1 · Cited by 136
Metabolism and Pharmacokinetics of the Antibiotic Rifampin
Kenny, M. T., & Strates, B. S. (1981) · Drug Metabolism Reviews · doi:10.3109/03602538109011084 · Cited by 136
Brogden, R. N., & Fitton, A. (1994) · Drugs · doi:10.2165/00003495-199447060-00008 · Cited by 131
Pharmacokinetics and Pharmacodynamics of Newer Fluoroquinolones
Stein, G. E. (1996) · Clinical Infectious Diseases · doi:10.1093/clinids/23.supplement_1.s19 · Cited by 130
de Jonge, M. R., Koymans, L. M. H., Guillemont, J., Koul, A., & Andries, K. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21376 · Cited by 124
Pharmacokinetic and Pharmacodynamic Issues in the Treatment of Mycobacterial Infections
Nuermberger, E. L., & Grosset, J. H. E. (2004) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-004-1109-5 · Cited by 123
In vitro antibacterial spectrum of a new broad-spectrum 8-methoxy fluoroquinolone, gatifloxacin
Fung-Tomc, J. C., Minassian, B., Kolek, B., et al. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/45.4.437 · Cited by 122
Choi, K.-P., Kendrick, N., & Daniels, L. (2002) · Journal of Bacteriology · doi:10.1128/jb.184.9.2420-2428.2002 · Cited by 108
Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of Moxifloxacin
WEINER, M. H., Burman, W. J., Luo, C.-C., et al. (2007) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01621-06 · Cited by 106
Fluoroquinolone Resistance in Patients with Newly Diagnosed Tuberculosis
Ginsburg, A. S., Hooper, N. R., Parrish, N. M., Dooley, K. E., Dorman, S. E., Booth, J., Diener‐West, M., Merz, W. G., Bishai, W. R., & Sterling, T. R. (2003) · Clinical Infectious Diseases · doi:10.1086/379328 · Cited by 105
Interspecies pharmacokinetics and in vitro metabolism of SQ109
Jia, L., Noker, P. E., Coward, L. C., et al. (2006) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0706650 · Cited by 102
Tasneen, R., Tyagi, S. K., Williams, K. N., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00686-08 · Cited by 101
Choi, K.-P., Bair, T., Bae, Y.-M., & Daniels, L. (2001) · Journal of Bacteriology · doi:10.1128/jb.183.24.7058-7066.2001 · Cited by 96
Clinical Pharmacokinetics of Rifabutin
Skinner, M., & Blaschke, T. F. (1995) · Clinical Pharmacokinetics · doi:10.2165/00003088-199528020-00003 · Cited by 92
Paramasivan, C. N., Sulochana, S., Kubendiran, G., Venkatesan, P., & Mitchison, D. A. (2005) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.49.2.627-631.2005 · Cited by 91
The search for new sterilizing anti-tuberculosis drugs
Denis, A. M. (2004) · Frontiers in bioscience · doi:10.2741/1293 · Cited by 89
Pharmacokinetics of Rifapentine at 600, 900, and 1,200 mg during Once-Weekly Tuberculosis Therapy
WEINER, M. H., BOCK, N. N., Peloquin, C. A., Burman, W. J., Khan, A., Vernon, A. A., Zhao, Z., Weis, S. E., Sterling, T. R., Hayden, K., et al. (2004) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200311-1612oc · Cited by 89
Clinical Pharmacology of the Fluoroquinolones: Studies in Human Dynamic/Kinetic Models
Schentag, J. J. (2000) · Clinical Infectious Diseases · doi:10.1086/314059 · Cited by 87
Bémer-Melchior, P., Bryskier, A., & Drugeon, H. (2000) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/46.4.571 · Cited by 85
Mor, N., Simon, B., Mezo, N., & Heifets, L. B. (1995) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.39.9.2073 · Cited by 81
The Rapid Development of Fluoroquinolone Resistance inM. tuberculosis
Ginsburg, A. S., Woolwine, S. C., Hooper, N. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejm200311133492023 · Cited by 79
Biomarkers of treatment response in clinical trials of novel antituberculosis agents
Perrin, F., Lipman, M. C. I., McHugh, T. D., et al. (2007) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(07)70112-3 · Cited by 73
Véziris, N., Ibrahim, M., Lounis, N., et al. (2008) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200711-1736oc · Cited by 70
Dickinson, J. M., & MITCHISON, D. A. (1987) · Tubercle · doi:10.1016/0041-3879(87)90053-5 · Cited by 70
Rifapentine, Moxifloxacin, or DNA Vaccine Improves Treatment of Latent Tuberculosis in a Mouse Model
Nuermberger, E. L., Tyagi, S. K., Williams, K. N., Rosenthal, I. M., Bishai, W. R., & Grosset, J. H. E. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200507-1047oc · Cited by 67
Tam, C. M., Chan, S. L., Chak Wah, L. A. M., et al. (1998) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/ajrccm.157.6.9707037 · Cited by 64
Bactericidal activity of OPC-67683 against drug-tolerant Mycobacterium tuberculosis
Saliu, O. Y., Crismale, C., Schwander, S., & Wallis, R. S. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm291 · Cited by 63
Dooley, K. E., Flexner, C. W., Hackman, J., et al. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00554-08 · Cited by 62
Lounis, N., Gevers, T., Berg, J. V. D., & Andries, K. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00566-08 · Cited by 60
Jarvis, B., & Lamb, H. M. (1998) · Drugs · doi:10.2165/00003495-199856040-00008 · Cited by 59
Novel Agents in the Management of Mycobacterium Tuberculosis Disease
Barry, P. J., & O'Connor, T. M. (2007) · Current Medicinal Chemistry · doi:10.2174/092986707781368496 · Cited by 51
Long-Term Tolerance and Effectiveness of Moxifloxacin Therapy for Tuberculosis: Preliminary Results
Valerio, G., Bracciale, P., Manisco, V., Quitadamo, M., Legari, G., & BELLANOVA, S. (2003) · Journal of Chemotherapy · doi:10.1179/joc.2003.15.1.66 · Cited by 50
Jia, L., Coward, L. C., Gorman, G. S., Noker, P. E., & Tomaszewski, J. E. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087817 · Cited by 48
Rifabutine: Minimal Inhibitory and Bactericidal Concentrations for Mycobacterium tuberculosis
Heifets, L. B., Lindholm-Levy, P. J., & Iseman, M. D. (1988) · American Review of Respiratory Disease · doi:10.1164/ajrccm/137.3.719 · Cited by 45
Mycobacterium leprae Is Naturally Resistant to PA-824
Manjunatha, U. H., Lahiri, R., Randhawa, B., Dowd, C. S., Krahenbuhl, J. L., & Barry, C. E. (2006) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00488-06 · Cited by 43
Tanoue, L. T. (2008) · Yearbook of Pulmonary Disease · doi:10.1016/s8756-3452(08)70748-5 · Cited by 37
Jia, L., Tomaszewski, J. E., Noker, P. E., Gorman, G. S., Glaze, E. R., & Protopopova, M. N. (2004) · Journal of Pharmaceutical and Biomedical Analysis · doi:10.1016/j.jpba.2004.11.036 · Cited by 33
Shortening the treatment of tuberculosis
Mitchison, D. A. (2005) · Nature Biotechnology · doi:10.1038/nbt0205-187 · Cited by 27
Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease
Mitchison, D. A. (1996) · Journal of Applied Bacteriology · doi:10.1111/j.1365-2672.1996.tb04600.x · Cited by 25
Modern methods for assessing the drugs used in the chemotherapy of mycobacterial disease
Mitchison, D. A. (1996) · Journal of Applied Microbiology · doi:10.1111/j.1365-2672.1996.tb04835.x · Cited by 22
NLCQ-1 and NLCQ-2, two new agents with activity against dormant Mycobacterium tuberculosis
Papadopoulou, M. V., Bloomer, W. D., & McNeil, M. (2007) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2007.01.015 · Cited by 21
(2008) · Tuberculosis · doi:10.1016/s1472-9792(08)70029-5 · Cited by 8
Cited by
Challenges of Antibacterial Discovery
Silver, L. L. (2011) · Clinical Microbiology Reviews · doi:10.1128/cmr.00030-10 · Cited by 1,376
Hurdle, J. G., O'Neill, A. J., Chopra, I., & Lee, R. E. (2011) · Nature Reviews Microbiology · doi:10.1038/nrmicro2474 · Cited by 871
O'Neill, T. E., Li, H., Colquhoun, C. D., Johnson, J. A., Webster, D., & Gray, C. A. (2014) · Phytochemical Analysis · doi:10.1002/pca.2516 · Cited by 31
Metadata
- Authors
- van den Boogaard, J., Kibiki, G. S., Kisanga, E. R., Boeree, M. J., & Aarnoutse, R. E.
- Venue
- Antimicrobial Agents and Chemotherapy
- Publisher
- American Society for Microbiology
- Published
- 2009-03
- Volume
- 53
- Issue
- 3
- Pages
- 849-862
- ISSN
- 0066-4804 (ISSN-L)
- 1098-6596
- OpenAlex
- W2151851241
- Cited by
- 257
- References
- 99
- FWCI
- 11.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.